RICERCA ITALIANA     

Programmi di ricerca simili:

• 1 - Trombosi arteriosa giovanile: identificazione della componente eredo-familiare
• 2 - FATTORI DI RISCHIO, MARKER DI DANNO ENDOTELIALE E FATTORI EMODINAMICI ASSOCIATI ALLA LEUCOENCEFALOPATIA SU BASE MICROVASCULOPATICA
• 3 - Epatopatia steatosica non alcolica : studio dei fattori metabolici, genetici e virologici responsabili del danno epatico e della sua evoluzione
• 4 - basi genetico molecolari dell'accidente cerebrovascolare
• 5 - MALATTIA PARODONTALE E RISCHIO DI PATOLOGIE CARDIOVASCOLARI:STUDIO DELL'ASSOCIAZIONE MEDIANTE MARKER CLINICI E DI LABORATORIO
• 6 - STUDIO EPIDEMIOLOGICO E GENETICO DELLA DEGENERAZIONE MACULARE SENILE
• 7 - Infiammazione e danno endoteliale nell'anziano: identificazione di marcatori di predisposizione genetica.
• 8 - Studio sui correlati biologici e clinici degli infarti cerebrali silenti
• 9 - STUDI SUI FATTORI GENETICI ED IMMUNOLOGICI CHE REGOLANO IL DANNO TESSUTALE ED IL DECORSO CLINICO DELL'ARTRITE REUMATOIDE
• 10 - Fattori di rischio infettivo e ruolo patogenetico di microrganismi nello sviluppo e progressione delle malattie vascolari

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze biologiche
  • BIOCHIMICA
• Area scientifico disciplinare: Scienze mediche
  • MEDICINA INTERNA
  • MALATTIE DELL'APPARATO CARDIOVASCOLARE
  • ENDOCRINOLOGIA

Classificazione brevettuale

• CHEMISTRY; METALLURGY
  • BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
• HUMAN NECESSITIES
  • MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • DIAGNOSIS; SURGERY; IDENTIFICATION (analysing biological material G01N, e.g. G01N33/48; obtaining records using waves other than optical waves, in general G03B42/00)
    • PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (bringing into special physical form A61J [N: mechanical aspects]; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; compounds per se C01, C07, C08, C12N; soap compositions C11D; micro-organisms per se C12N) [C0203]

Classificazione geografica

• Regione: Veneto

Bibliografia

Bernardi F, Arcieri P, Bertina RM, Chiarotti F, Corral J, Pinotti M, Prydz H, Samama M, Sandset PM, Strom R, Vicente Garcia V, Mariani G. Contribution of Factor VII genotype to activated FVII levels. Differences in genotype frequencies between Northern and Southern European population. Arterioscl. Thromb. Vasc. Biol. 1997;17:2548-53.
Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Bonadonna R, Muggeo M (2003): The metabolic syndrome: epidemiology and more extensive phenotypic description. Int J Obes Relat Metab Disords 27: 1283-1289.
Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Bonadonna R, Muggeo M (2003): Carotid atherosclerosis and coronary heart disease in the metabolic syndrome. Prospective data from the Bruneck Study. Diabetes Care 26: 1251-1257.
Bonora E, Willeit J, Kiechl S, Oberhollenzer F, Egger G, Bonadonna R, Muggeo M (1997): Relationship between insulin and carotid atherosclerosis in the general population. The Bruneck Study. Stroke 28: 1147-1152.
Boucher P and Gotthardt M. LRP and PDGF Signaling: A Pathway to Atherosclerosis. Trends Cardiovasc Med 2004;14:55–60.
Cardon LR and Bell JI. Association study designs for complex disease. Nat Rev Genet 2001; 2:91-99.
Geschwind DH. DNA microarrays: translation of the menome from laboratory to clinic. Lancet Neurol 2003; 2:275-82.
Girelli D, Russo C, Ferraresi P, Olivieri O, Pinotti M, Friso S, Manzato F, Mazzucco A, Bernardi F, Corrocher R. Polymorphisms in the Factor VII gene and risk of myocardial infarction in patients with coronary artery disease. N. Engl. J. Med. 2000;343:774-80.
Gluckman TJ, Baranowski B, Ashen MD, Henrikson CA, McAllister M, Braunstein JB, Blumenthal RS (2004): A practical and evidence-based approach to cardiovascular disease risk reduction. Arch Intern Med 164:1490-500.
Gomma AH, Hirschfield GM, Gallimore JR, Lowe GD, Pepys MB, Fox KM: Preprocedural inflammatory markers do not predict restenosis after successful coronary stenting. Am Heart J 2004;147(6):1071-1077.
Gorchakova O, Koch W, von Beckerath N, Mehilli J, Schomig A, Castrati A. Association of a genetic variant of endothelial nitric oxide synthase with the 1 year clinical outcome after coronary stent placement. European Heart Journal 2003;24:820–27.
Grundy SM (2004): Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 89:2595-600.
Handschug K, Schulz S, Schnurer C, Kohler S, Wenzel K, Teichmann W, Glaser C. Low-density lipoprotein receptor-related protein in atherosclerosis development: up-regulation of gene expression in patients with coronary obstruction. J Mol Med. 1998;76:596-600
Helgadottir A, et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 2004; 36:233-9.
Hingorani AD. Polymorphisms in endothelial nitric oxide synthase and atherogenesis. John French Lecture 2000. Atherosclerosis 2000;154:521–527.
Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002; 347:969-74.
Kiechl S, Willeit J (1999): The natural course of atherosclerosis. Part I: incidence and progression. Arterioscler Thromb Vasc Biol 19: 1484-1490.
Kiechl S, Willeit J (1999): The natural course of atherosclerosis. Part II: vascular remodeling. Arterioscler Thromb Vasc Biol 19: 1491-1498.
Kiechl S, Willeit J, Rungger G, Egger G, Oberhollenzer F, Bonora E (1998): Alcohol consumption and atherosclerosis: What is the relation? Prospective results from the Bruneck Study. Stroke 29: 900-907
Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG, and the MTHFR Studies Collaboration Group°. MTHFR 677CT polymorphism and risk of coronary heart disease. A meta-analysis. JAMA 2002; 288:2023-31
Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-74.
Manolio TA, Boerwinkle E, O’Donnell CJ, Wilson AF. Genetic of ultrasonographic carotid atherosclerosis. Arterioscler Thromb Vasc Biol. 2004;24:1567-77.
Marchetti G, Gemmati D, Patracchini P, Pinotti M, Bernardi F. PCR detection of a repeat polymorphism within the F7 gene. Nucleic Acids Res. 1991;19:4570.
Molavi B, Mehta JL (2004): Oxidative stress in cardiovascular disease: molecular basis of its deleterious effects, its detection, and therapeutic considerations. Curr Opin Cardiol. 19:488-493.
Peppelenbosch MP, Versteeg HH. Cell biology of tissue factor, an unusual member of the cytokine receptor family. Trends Cardiovasc Med. 2001;11:335-9.
Piatti P, Di Mario C, Monti L et al. Association of Insuline Resistance, Hyperleptinemia, and Impaired Nitric Oxide Release With In-Stent Restenosis in Patients Undergoing Coronary Stenting. Circulation, 2003;108:2074-2081.
Plutzky J (2003): The vascular biology of atherosclerosis. Am J Med 115 Suppl 8A:55S-61S.
Reny JL, Laurendeau I, Fontana P, Bieche I, Dupont A, Remones V, Emmerich J, Vidaud M, Aiach M, Gaussem P. The TF-603A/G gene promoter polymorphism and circulating monocyte tissue factor gene expression in healthy volunteers. Thromb Haemost. 2004;91:248-54.
Ribichini F, Ferrero V, Matullo G, Feola M, Vado A, Camilla T, Guarrera S,Carturan S, Vassanelli C, Uslenghi E, Piazza A. Association study of the I/D polymorphism and plasma angiotensin-converting enzyme (ACE) as risk factors for stent restenosis. Clin Sci 2004;107(4):381-9.
Ridker PM (2003): Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107: 63-69
Roldan V, Marin F, Lip GY, Blann AD (2003): Soluble E-selectin in cardiovascular disease and its risk factors. A review of the literature. Thromb Haemost 90:1007-20.
Rose N and Afanasyeva M. Autoimmunity: busting the atherosclerotic plaque. Nat Med 2003; 9:641-2.
Schwartz RS. Pathophysiology of restenosis: interaction of thrombosis, hyperplasia, and/or remodeling. Am J Cardiol 1998;81:14E-17E.
Shishehbor MH, Bhatt DL (2004): Inflammation and atherosclerosis. Curr Atheroscler Rep 6:131-139.
Sobel BE. Acceleration of Restenosis by Diabetes. Pathogenetic Implications. Circulation. 2001;103:1185-1187 (Editorial).
Stephens JW and Humphries SE. The molecular genetics of cardiovascular disease. J Intern Med 2003; 253:120-7.
Tutar E, Ozcan M, Kilickap M, Gulec S, Aras O, Pamir G, Oral D, Dandelet L, Key NS. Elevated whole-blood tissue factor procoagulant activity as a marker of restenosis after percutaneous transluminal coronary angioplasty and stent implantation. Circulation. 2003;108:1581-4.
Versaci F, Gaspardone A, Tomai F, Ribichini F, Russo P, Proietti I Ghini AS, Ferrero V, Chiariello L, Gioffre`, Romeo PA, Crea F. Immunosuppressive Therapy for the Prevention of Restenosis After Coronary Artery Stent Implantation (IMPRESS Study)
Wang X, et al. Positional identification of TNFSF4, encoding OX40 ligand, as gene that influences atherosclerosis susceptibility. Nat Genet 2005; 37:365-372.
Wein TH and Bornstein NM. Stroke prevention: cardiac and carotid-related stroke. Neurol Clin 2000; 18:321-41.
Welt FGP, Rogers C. Inflammation and Restenosis in the Stent Era (Arterioscler Thromb Vasc Biol. 2002;22:1769-1776.)
Xu Q, Willeit J, Marosi M, Kleindienst R, Oberhollenzer F, Kiechl S, Stulnig T, Luef G, Wick G (1993): Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis. Lancet 341: 255-259.

Parole Chiave

ATEROSCLEROSI; CORONAROPATIA; POLIMORFISMI GENETICI; MALATTIE CARDIOVASCOLARI; RESTENOSI